Why Weight Loss Stalls on GLP-1s (And What Actually Helps)
A weight loss plateau on a GLP-1 medication can feel like the medication has simply stopped working. The research tells a more precise story: plateaus are a predictable, physiological response your body mounts against sustained weight loss — and understanding the actual mechanism points toward what genuinely helps.
The real mechanism: adaptive thermogenesis
Recent research describes the core process clearly: GLP-1 receptor-based obesity therapies like semaglutide and tirzepatide can reduce lean muscle mass and energy expenditure through a process called adaptive thermogenesis, also known as metabolic adaptation — and this is a leading contributor to weight loss plateaus and subsequent regain (ScienceDirect, 2025). In plain terms: as you lose weight, your body's energy expenditure drops by more than would be expected from the weight loss alone, partly because you're carrying less muscle, which is metabolically active tissue that burns energy even at rest.
This isn't unique to semaglutide or tirzepatide. Similar weight loss plateaus and regain patterns have been observed in the SURMOUNT-4 trial for tirzepatide, in the first Phase 3 trial of the GLP-1/glucagon dual agonist mazdutide, and in a Phase 2 trial of the GLP-1/GIP/glucagon tri-agonist retatrutide (ScienceDirect, 2025) — suggesting this is a fundamental feature of how these medications interact with the body's own defence mechanisms, not a flaw specific to one drug.
Why GLP-1 plateaus look different from diet-only plateaus
A modelling study comparing calorie restriction, semaglutide, tirzepatide, and bariatric surgery found something genuinely interesting: unlike simple calorie restriction, semaglutide, tirzepatide, and gastric bypass surgery all appear to weaken the body's normal appetite feedback control circuit, resulting in an extended period of weight loss before the plateau eventually occurs (Physiology of the Weight Loss Plateau, bioRxiv, 2023). In the same modelling work, tirzepatide showed a distinctive pattern: a rapid initial drop in energy intake during dose escalation, followed by intake gradually increasing again over time, approaching a new equilibrium as the plateau phase set in (Physiology of the Weight Loss Plateau, bioRxiv, 2023).
This matters practically: it means the plateau isn't simply "the drug wearing off" — it's your body's intake and expenditure systems recalibrating around the new, lower weight, in a way that behaves differently to how plateaus happen on diet alone.
Muscle: not just a side effect, but part of the plateau mechanism itself
This is genuinely one of the more important findings for anyone approaching a plateau practically. Research specifically investigating this connection frames it directly in its title: can preserving muscle avert GLP-1 receptor-related weight plateaus and regain? (ScienceDirect, 2025). The research indicates that defining the role of muscle-related energy expenditure in mediating plateaus is considered critical to improving how these medications are used long-term (ScienceDirect, 2025), and that strategies which preserve or enhance energy expenditure pathways — muscle being a central one — are likely necessary to maximise long-term, sustainable weight loss (ScienceDirect, 2025).
In other words: muscle preservation isn't just about avoiding an unwanted side effect on the scale — current research suggests it may be directly involved in whether or not you plateau, and how much weight you regain if you do.
Rodent research on why appetite suppression itself may not be constant
Separate animal research adds another layer: chronic studies show that the reduction in food intake caused by GLP-1 receptor agonists is transient in rodent models, rather than a constant, unchanging effect throughout treatment (Chronic Semaglutide Treatment Study, bioRxiv, 2025). While this research is in mice rather than humans, it points toward the same underlying idea — that the body doesn't simply respond to a GLP-1 medication the same way indefinitely, and some degree of physiological adaptation over time is a real, biologically grounded phenomenon, not just a subjective impression.
What this means practically
Given the current evidence, a few practical implications follow directly:
A plateau isn't evidence the medication has stopped working or that you've done something wrong. It's a well-documented physiological response, observed consistently across multiple different GLP-1-based medications in trial data.
Muscle preservation is directly implicated in the plateau mechanism itself, not just a separate concern about body composition — which reinforces why resistance training and adequate protein intake, covered in our guide to preventing muscle loss on a GLP-1, matter as much for breaking through a plateau as for general health.
This is an active area of genuine scientific interest, with ongoing research explicitly aimed at finding therapeutic strategies to address plateau-driving mechanisms directly (ScienceDirect, 2025) — meaning the understanding of this problem, and the tools to address it, are actively evolving.
Where a plateau becomes a conversation with your prescriber
If your weight loss has genuinely stalled for an extended period despite consistent adherence to your medication and nutrition plan, this is worth raising directly with your prescriber — dose adjustments and other clinical considerations are legitimate parts of the conversation, not something to work around on your own.
Why addressing this needs more than patience
Given what the research actually shows — that muscle loss and reduced energy expenditure are directly implicated in why plateaus happen — waiting out a plateau passively misses the point. The mechanism itself points toward action: protecting and building muscle through structured training and adequate protein intake.
This is exactly the strategy our While You're On It programme is built around — resistance training guidance and protein targets designed specifically to address the muscle and energy-expenditure side of the plateau equation, not just calorie counting.
If getting enough protein to support that muscle-preservation goal is difficult on a suppressed appetite, our Alongside Daily Support powder can help you consistently hit your targets.
Because the same adaptive mechanisms driving plateaus are also implicated in weight regain after stopping treatment, our Coming Off It programme is built with this research directly in mind for the maintenance phase.
And if you're currently experiencing a plateau and want a structured review of your training, nutrition, and overall approach, our 1:1 coaching can help you work through it methodically.
The bottom line
Weight loss plateaus on GLP-1 medications aren't a sign of failure — they're a well-documented physiological response called adaptive thermogenesis, involving reduced muscle mass and energy expenditure, observed consistently across semaglutide, tirzepatide, and other newer incretin-based medications in trial data. Muscle preservation appears to be directly implicated in the plateau mechanism itself, which is exactly why resistance training and adequate protein intake are increasingly viewed by researchers as central tools for sustaining weight loss, not just supporting side details.
This article is for general information and isn't a substitute for medical advice. If your weight loss has plateaued for an extended period, speak to your prescriber about your specific treatment plan.
References
Can muscle avert GLP1R weight plateau and regain? (2025, September 16). ScienceDirect. https://www.sciencedirect.com/science/article/pii/S2666379125003817
Chronic semaglutide treatment reveals stage-dependent changes to feeding behavior and metabolic adaptations in male mice. (2025). bioRxiv. https://www.biorxiv.org/content/10.1101/2025.07.24.666640.full.pdf
Physiology of the weight loss plateau after calorie restriction, GLP-1 receptor agonism, and bariatric surgery. (2023). bioRxiv. https://www.biorxiv.org/content/10.1101/2023.11.05.565699.full.pdf
Comments